Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.

• Main Authors: Livingstone Tavul (Author), Moses Laman (Author), Cade Howard (Author), Bethuel Kotty (Author), Anna Samuel (Author), Catherine Bjerum (Author), Kobie O'Brian (Author), Steven Kumai (Author), Matthew Amuga (Author), Lina Lorry (Author), Zebedee Kerry (Author), Melvin Kualawi (Author), Stephan Karl (Author), Leo Makita (Author), Lucy N John (Author), Sibauk Bieb (Author), James Wangi (Author), Gary J Weil (Author), Charles W Goss (Author), Daniel J Tisch (Author), William Pomat (Author), Christopher L King (Author), Leanne J Robinson (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<h4>Background</h4>Papua New Guinea (PNG) has a high burden of lymphatic filariasis (LF) caused by Wuchereria bancrofti, with an estimated 4.2 million people at risk of infection. A single co-administered dose of ivermectin, diethylcarbamazine and albendazole (IDA) has been shown to have...